DJIA 17,813.39 1.20 0.01%
NASDAQ 5,116.14 13.34 0.26%
S&P 500 2,088.87 -0.27 -0.01%
market minute promo

68.08 0.26 (0.38%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

BMY $68.08 0.38%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $67.82
Previous Close $67.82
Daily Range $67.59 - $68.45
52-Week Range $51.82 - $70.54
Market Cap $113.6B
P/E Ratio 63.98
Dividend (Yield) $1.48 (2.2%)
Ex-Dividend Date
Dividend Pay Date
Volume 3,701,938
Average Daily Volume 5,725,421
Current FY EPS $1.89




Drug Makers

Bristol-Myers Squibb Co. (BMY) Description

Bristol-Myers Squibb discovers, develops, licenses, makes, and sells pharmaceuticals, with particular success in cardiovascular treatments. Website:

News & Commentary Rss Feed

Why Aduro Biotech Is Crashing Today

A set back for a promising new therapy for pancreatic cancer is weighing on shares.

Bristol-Myers' Opdivo Gets FDA Nod for Another Indication

Clinton's Price Caps Are A Non-Starter: Liana Moussatos Of Wedbush Securities

Premarket Biotech Digest: CTI BioPharma Undervalued, Shire's New Bid, BioMarin's DMD Drug Review

Bristol-Myers' Opdivo Label Now Includes Renal Cell Cancer

FDA approves expanded use of Bristol-Myers' skin cancer drug

Bristol-Myers Squibb Announces U.S. Food and Drug Administration Approval for Opdivo (nivolumab) as

Bristol-Myers Squibb Announces U.S. Food and Drug Administration Approval for Opdivo (nivolumab) as a Single Agent for the Treatment of Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma

5 Dividend Stocks to Buy in November

These five companies can provide years of steady payouts for patient investors.

FDA approves Bristol's Opdivo for kidney cancer

These 10 S&P 500 Health Care Companies Are the Most Shareholder Friendly

See More BMY News...

BMY's Top Competitors

BMY $68.08 (0.38%)
Current stock: BMY
JNJ $101.96 (-0.08%)
Current stock: JNJ
NVS $85.95 (-0.52%)
Current stock: NVS
RHHBY $33.19 (0.90%)
Current stock: RHHBY